Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

The latest cuts, which are part of a larger reduction of 10,000 at the Department of Health and Human Services, were ...

The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The ...

Cell therapy and oncology–focused Carisma Therapeutics started layoffs late last year. Now the company plans to wind down ...

Analysts at financial firm Cantor Fitzgerald are urging President Donald Trump to rethink his appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services.

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Bluebird bio on Friday confirmed it has received an unsolicited take-over offer from the Ireland-based investment firm Ayrmid ...